natgillin/translations-raw huggingface dataset:
an antibody variant which comprises the main species HER2 antibody and an amino-terminal leader extension that comprises VHS- on a light chain of the antibody variant, 
varijanta protutijela, koja sadrži glavni rod HER2-protutijela i amino-završno predvodeće produljenje koje sadrži VHS- na slabom lancu varijante protutijela;
The compositions above are specific examples of preferred embodiments of the invention, wherein an M3 antagonist of Formula I is combined with a corticosteroid. 
Gornji su pripravci specifični primjeri poželjnih utjelovljenja sukladno predmetnom izumu, kod kojih se M3 antagonist sukladno predmetnom izumu kombinira s B2-agonistom.
wherein the first integrated circuitry comprises a first cryptographic engine to securely transfer the sensitive data based on the symmetrical crypto method using the active secure key which is replaceable by the new secure key generated by the second integrated circuitry after power up. 
- gdje prvi integrirani krug (10) sadrži sredstvo za šifriranje, namijenjeno sigurnom prijenosu osjetljivih podataka postupkom simetričnog šifriranja u kojem se upotrebljava aktivni sigurnosni ključ kojeg se može zamijeniti navedenim novim sigurnosnim ključem, kojeg generira drugi integrirani krug (20) nakon uključivanja.
The method of either of claims 1 or 2, wherein the subject has multiple sclerosis (MS) or Crohn's Disease (CD). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što subjekt ima multiplu sklerozu (MS) ili Crohnovu bolest (CD).
A process according to claim 1 for the manufacture of the compound of formula or a tautomer or salt thereof, comprising 
Postupak u skladu sa zahtjevom 1 za pripravu spoja formule m Y MOO va
In a preferred embodiment, the surface-reacted natural calcium carbonate has a specific surface area of from 5 m2/g to 200 m2/g, more preferably 20 m2/g to 80 m2/g and even more preferably 30 m2/g to 60 m2/g, measured using nitrogen and the BET method according to ISO 9277. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu površinski-reagirani prirodni kalcij karbonat ima specifičnu površinu od oko 5 m*/g do 200 m'/g, mjereno koristeći dušik i BET metodu u skladu sa ISO 9277.
The method according to claim 7, wherein the TLR ligand is an imidazoquinoline selected from the group consisting of imidazoquinoline, imiquimod, resiquimod, CpG oligodeoxynucleotides LPSs (lipopolysaccharides) and poly(inosinic acid)-poly(cytidylic acid). 
Pripravak za uporabu prema zahtjevu 8, naznačen time da je TLR ligand odabran od imidazokinolina koji pripadaju skupini koja sadrži imidazokinolin, imikvimod, rezikvimod, CpG oligodeoksinukleotidne LPS (lipopolisaharide) ili poli(inozinsku kiselinu)-poli(citidilnu kiselinu).
Typically the closure wall of such a closure has a thickness ca. 2 mm. 
Tipično je da stijenka zatvarača takvog zatvarača ima debljinu oko 2 mm.
a dye affinity chromatography, an optional cation exchange chromatography, 
Cc) afinitetna kromatografija prema bojama, d) opcionalna kationska izmjenjivačka kromatografija,
The method according to claim 10, wherein the L1 block has L1 signaling information for signaling the at least one data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što LI blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
<13> a (C1-8 alkyl)m8d-amino group which may be substituted by one or more R8B4, 
(10) Cos alkoksi(Cgg alkil)-aminokarbonilna skupina, koja može biti supstituirana s jednom ili više hidroksi skupina,
In specific embodiments, provided herein is a pharmaceutical composition suitable for topical application to an ocular surface comprising a therapeutically effective amount of PRG4 suspended in an ophthalmically acceptable balanced salt solution, and may also be in combination with one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, an ophthalmically acceptable excipient, an ophthalmically acceptable astringent, an ophthalmically acceptable vasoconstrictor, and an ophthalmically acceptable emollient. 
Farmaceutska kompozicija za primjenu u liječenju nedostatka okularne lubrikacije ili simptoma udruženih sa njim koja sadrži PRG4 ili njegov fragment za lubrikaciju u kombinaciji sa terapijski efikasnom koncentracijom PRG4- inducirajućeg spoja odabranog iz grupe koja se sastoji od androgena, selektivnog modulatora receptora androgena, i analoga androgena, pri čemu navedeni analog androgena je odabran iz grupe koja se sastoji od 17a-metil-17f- hidroksi-2-oksa-5a-androstan-3-ona, 4,5a-dihidrotestosterona, i 19-nortestosterona, pri čemu navedeno liječenje obuhvaća topikalnu administraciju navedenog spoja na okularnu površinu.
loading the diafiltered sample on a cation exchange column for purification in bind and elute mode; 
punjenje dijaflitriranog uzorka u kolonu za kationsku razmjenu za pročišćavanje u modusu vezanja i razrjeđivanja (104);
A host cell according to claim 10, wherein the DNA sequence encoding the light chain comprises the sequence given in SEQ ID NO:14 or SEQ ID NO:17 or nucleotides 61-705 of SEQ ID NO:17. 
Stanica domaćin prema zahtjevu 10, naznačena time da DNK sekvenca koja kodira laki lanac sadrži sekvencu datu u SEQ ID NO: 14:ili SEQ ID NO: 17 ili nukleotide 61-705 sekvence SEQ ID NO: 17.
The system of claim 11, wherein the intracellular oxygen booster is Tropaeolum Majus Flower/Leaf/Stem Extract; the emulsifier is a nonionic, cationic, anionic or polymeric emulsifier; the rheology modifier is a polyacrylic acid polymer, xanthan gum, cellulose gum, silicate, alginate, or hydrocolloid; the humectant is propanediol, glycerin or another glycol; the surfactant is cationic, anionic, ethoxylated or non-ethoxylated; the antimicrobial agent is salicylic acid or a preservative; the colorant is an FD&C color, iron oxide, or titanium dioxide; the aroma is in the form of a fragrance or essential oil; and the antioxidant is ascorbic acid. 
Formulacija prema zahtjevu 7, naznačena time što je unutarstanični pojačivač kisika ekstrakt cvijeta/lista/stabljike Tropaeolum majus; emulgator je neionski, kationski, anionski ili polimerni emulgator; reološki modifikator je polimer poliakrilne kiseline, ksantan guma, celulozna guma, silikat, alginat ili hidrokoloid; ovlaživač je propandiol, glicerin ili drugi glikol; surfaktant je kationski, anionski, etoksilirani ili ne-etoksilirani; antibakterijsko sredstvo je salicilna kiselina ili konzervans; boja je FD&C - boja, željezov oksid ili titanijev oksid; aroma je u obliku mirisne tvari ili eteričnog ulja; i antioksidacijsko sredstvo je askorbinska kiselina.
is selected from hydrogen and C1-20alkyl; 
R' je odabran od vodika i C, 2oalkila;
Kits used for assessment of the serum biomarkers: 
Datum objave europskog patenta:
The vector of claim 4 wherein the pathogen specific antigen is derived from a human immunodeficiency virus, simian immunodeficiency virus, or Mycobacterium tuberculosis. 
Vektor prema patentnom zahtjevu 4, naznačen time, da je patološki specifičan antigen izveden iz virusa humane imunodeficijencije, simian virusa imunodeficijencije ili Mycobacterium tuberculosis.
In another aspect, the invention is directed to a pharmaceutical composition comprising the aforementioned rapamycin carbohydrate derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
U još jednom aspektu, ovaj izum usmjeren je na farmaceutske pripravke koji sadrže prethodno spomenuti ugljikohidratni derivat rapamicina ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljiv nosač.
Process for obtaining very low molecular weight heparin (VLMWH) and low molecular weight heparin (LMWH) characterised in that consists the steps of: 
Proces za dobivanje heparina vrlo niske molekularne mase (VLMWH) i heparina niske molekularne mase (LMWH) okarakterizirano time da se sastoji od koraka:
Process according to claim 1, wherein the oxazolone of formula (3) is obtained from (16) and immediately reacted, without isolation and purification, with intermediate (4) to give the final product ibodutant. 
Postupak prema patentnim zahtjevima 1 1 5, naznačen time da oksazolon formule (3), dobiven iz spoja (16), bez izolacije i pročišćavanja odmah reagira s međuproduktom (4) dajući konačni produkt ibodutant.
pH stability of Alkaloid (nicotine) containing Lozenges with Citrate Buffer stored at 25° C./60% RH. 
HR P20080289 T3 pH stabilnost tableta koje sadrže alkaloid (nikotin) sa citratnim puferom čuvane na 252%C/60% relativne vlažnosti
in the regeneration reaction reconverting the oxidized cofactor into its original reduced form, a (C4-C8)-cycloalkanol or a compound of general formula 
u regeneracijskoj reakciji koja obnavlja oksidirani kofaktor u svom izvornom reduciranom obliku, (C4-Cg)-cikloalkanol ili spoj opće formule
a Rous sarcoma virus vector, and any derivative thereof. 
(q) vektor virusa Rousovog sarkoma i
Then a compound of formula VII is added successively. 
B) reakciji spoja formule VI s spojem formule VII
Another preferred embodiment of the present invention is the compound of Formula (I) wherein R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, or tetrahydrofuranyl; and R2 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R' (C,-Cs)alkil, (C3-Cy)cikloalkil ili tetrahidrofuranil; a R" je vodik ili metil; ili njegova farmaceutski prihvatljiva sol.
The tool may further include a sleeve, wherein the cutting blade is at least partially slidably disposed within the sleeve. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 8, naznačen time, da alat dodatno obuhvaća naglavak (304), pri čemu je nož za rezanje barem djelomično klizno postavljen unutar naglavka.
A compound of the formula I: wherein: 
1. Spoj formule I: gdje:
The compound of any of claims 1-8, wherein R5 is hydrogen or methyl. 
Spoj prema jednom od patentnih zahtjeva 1 do 13, naznačen time, da R5 je vodik ili metil.
Also preferred is an extended release tablet formulation, wherein the anionic polymer is selected from the group of optionally crosslinked acrylic acid polymers, methacrylic acid polymers, alginates, and carboxymethylcellulose. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da je anionski polimer izabran iz skupine koju čine po želji umreženi polimeri akrilne kiseline, polimeri metakrilne kiseline, alginati i karboksimetilceluloza.
The composition of any one of the preceding claims, wherein the enteric coating comprises film-forming substances, preferably cellulose acetate phthalate, polyvinyl- acetate phthalate, hydroxypropyl-methyl cellulose phthalate, hydroxypropyl-methyl cellulose acetate succinate, ethylacrylate methacrylic acid copolymer, methylmethacrylate methacrylic acid copolymer, shellac, preferably copolymers of methacrylic acid and methacrylic acid esters such as anionic polymer of methacrylic acid and methacrylates with -COOH groups. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da enterička obloga obuhvaća tvari za HR P20170591 T1 formiranje filma, poželjno su to celulozni acetat-ftalat, polivinil-acetat-ftalat, hidroksipropilmetil-celuloza- ftalat,hidroksipropilmetil-celuloza-acetat-sukcinat, kopolimer etilakrilat-metakrilne kiseline, kopolimer metilmetakrilat-metakrilne kiseline, šelak, poželjno kopolimeri metakrilne kiseline i esteri metakrilne kiseline kao što su anionski polimer metakrilne kiseline i metakrilati s -COOH-skupinama.
The dispensing head can, for example, have an operating arm that can operate a pin that can be moved up and down in the outflow end in order to move a ball valve. 
Glava raspršivača može, na primjer, imati upravljačku ruku koja može upravljati izdankom koji se može kretati gore i dolje na izlaznom kraju tako da pokreće kuglasti ventil.
We have surprisingly found that while both the Na-HA and the Zn2+ were ineffective alone, various doses of Zn-HA with different molecular weights inhibited the EAE induced in the model animals. 
Iznenađujuće smo pronašli da dok su oba Na-Hai Zn?* neučinkoviti zasebno, različite doze Zn-Ha sa različitim molkularnim težinama inhibiraju EAE induciran u modelu sa životinjama.
The salt according to claim 7, which salt is the glutamic acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
11. Sol prema zahtjevu 7, pri čemu je to adicijska sol glutaminske kiseline 4-[2-(4- metilfenilsulfaniDfenil] piperidina.
A compound according to claim 6, wherein R1 is (C2-C6)alkenyl, aryl, halogen, aryl-S-, heteroaryl or aryl(C1-C6)alkyl, wherein said aryl or heteroaryl as such or as part of another group is unsubstituted or substituted with 1 or 2 substituent(s) R6; 
. Spoj u skladu s patentnim zahtjevom 6, naznačen time, da Ri je (C2-Cs)alkenil, aril, halogen, aril-S-, heteroaril ili ari(C;-Cg)alkil, pri čemu rečeni aril ili heteroaril kao takva ili
at least one active agent, to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least 5 minutes. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 22, naznačen time da je u obliku tablete koja je napravljena izravnom kompresijom sastojaka i sušena najmanje podvrgavanjem navedene tablete na temperaturu od barem oko 60 °C ili pri barem oko 62 °C u vremenskom razdoblju od barem oko 1 minute, poželjno barem oko 5 minuta ili barem oko 15 minuta.
Embodiment 2 The polymer of embodiment 1 wherein Formula 1, Formula 2 and Formula 3 correspond to the following structures: 
Oralni oblik doziranja prema zahtjevu 1 naznačen time što Formula 1, Formula 2 i Formula 3 odgovaraju slijedećim strukturama:
The compound or salt according to claim 1, which is a compound represented by the formula (I) wherein R1 is a morpholino group optionally substituted by C1-6 alkyl group(s), a di(C1-6 alkyl)amino group, a C1-6 alkoxy group optionally substituted by C3-6 cycloalkyl group(s), a C3-6 cycloalkyl group or a C3-6 cycloalkenyl group; and R2 is a hydrogen atom or a C1-6 alkyl group. 
Spoj ili sol prema zahtjevu 1, naznačen time, da je spoj predstavljen formulom (I) [image] gdje je morfolino-skupina opcijski supstituirana s jednom ili više C1-6 alkil-skupina, di(C1-6 alkil)amino-skupina, C1-6 alkoksi-skupina opcijski supstituirana s jednom ili više C3-6 cikloalkil-skupina, C3-6 cikloalkil-skupina ili C3-6 cikloalkenil-skupina; i R2 je atom vodika ili C1-6 alkil-skupina.
A composition comprising the immunobinder of any one of items 1, 2, 11, 12 or 14 and a pharmaceutically acceptable carrier. 
Sastav, naznačen time, da obuhvaća imunovezno sredstvo prema bilo kojem od zahtjeva 1, 2, 11, 12 ili 13, te farmaceutski prihvatljiv nosač.
Buffer may be added to the microaggregate composition e.g. 
Sastavu mikroagregata se može dodati pufer, na pr.
The pharmaceutical composition according to claim 19, wherein Omega-3 fatty acids other than EPA and DHA are present in an amount of at least 1.5% by weight of the total fatty acids. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 17, naznačen time što su omega-3 masne kiseline koje nisu EPA i DHA prisutne u količini od najmanje 1,5 %, težinski, od ukupnih masnih kiselina.
A process as claimed in claim 8 or 9, wherein the suitable base is either dissolved or suspended in a polar aprotic solvent such as dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), dimethylacetamide (DMA),) and includes the mixture of these solvents in varying proportions. 
Postupak prema patentnom zahtjevu 8 ili 9, naznačen time što je pogodna baza ili otopljena ili suspendirana u polarnom aprotonskom otapalu kao što je dimetil formamid (DMF), dimetil sulfoksid (DMSO), dimetilacetamid (DMA), i obuhvaća smjesu ovih otapala u različitim proporcijama.
The modified release pharmaceutical composition of claim 3, wherein the cellulose ether polymer is hypromellose, hydroxypropyl ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose or a combination thereof. 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, gdje se polimer koji bubri u vodi i pH je neovisan izabire iz grupe koja obuhvaća hipromelozu, hidroksipropil etil celuloze, hidroksipropil celulozu, hidroksietil celulozu, metil celulozu i njihove kombinacije.
values measured are quantifiable on the IFN-Y Standard curve. 
koje su izmjerene su prikladne za Standardne krivulje za INF-y.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to any one of claims 1-13. 
Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač 1 farmaceutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-13.
Wind system (1) according to claim 1, characterised in that said recovering system (8) is made of a trellis-type structure. 
Vjetreni sustav (1) prema zahtjevu 7, naznačen time da su spomenuti permanentni magneti magneti od spoja neodimijuma, željeza i borona.
Compositions for rectal use are prepared in manner known per se in the form of suppositories which besides the active ingredient contain also a carrier, usually cocoa butter. 
Sastavi namijenjeni rektalnoj upotrebi se pripravljaju na dobro poznate načine u obliku supozitorija koji osim aktivne tvari također sadrže i nosač, koji je obično kakaov maslac.
In a preferred embodiment, a tumor-associated antigen identified according to the invention has an amino acid sequence encoded by a nucleic acid which is selected from the group consisting of SEQ ID NOs: 1-8, 41-44, 51-59, 84, 117, 119 and 138. 
Farmaceutska kompozicija za primjenu prema bilo kojem od zahtjeva 1-3, pri čemu antigen povezan s tumorom sadrži aminokiselinsku sekvencu koja je izabrana iz grupe koja se sastoji od SEQ ID NOs: 16-19, 112, 113, 116, 137 i 142-145.
The pyridone derivative, or a salt thereof, according to any of (1) to (3), wherein R2 in the formula (I) represents a hydrogen atom, a halogen atom, a C1-C6 alkoxy group, or a C1-C6 alkyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 3, naznačen time da je R* u formuli (I) atom vodika, atom halogena, C1-C6 alkoksi grupa,ili C1-C6 alkil grupa.
Methods for the preparation and delivery of fuel compositions 
POSTUPAK ZA PRIPREMU I PROVEDBU SMJESE GORIVA
the sum total of the first homology arm and the second homology arm is at least about 10 kb; and/or 
prvi vektor koji ciljno djeluje je najmanje oko 10 kb ili je od oko 20 kb do oko 300 kb; i/ili
A compound of formula (1f): 
Spoj naznačen time da ima formulu (17):
The compound of Example 1 was extensively hydrolyzed in vivo to release gemcitabine when administered orally to CD-1 mice. 
Spoj iz Primjera 1 u znatnoj se mjeri hidrolizira in vivo, otpuštajući gemcitabin prilikom oralne primjene na CD-1 miševima.
The composition of claims 1 to 15, comprising 10-20%, preferably 12-21%, preferably 15% medium chain fatty acid salt preferably sodium octanoate, 5-10%, preferably 10% PVP-12, and wherein the hydrophobic medium comprises 20-80%, preferably 30-70% triglyceride preferably glyceryl tricaprylate or glyceryl tributyrate or castor oil or a mixture thereof, 3-10% surfactants, preferably 6% glyceryl monocaprylate and polyoxyethylene sorbitan monooleate and about 1% water and wherein the therapeutic agent is present at an amount of less than 33%, or less than 25%, or less than 10 %, or less than 1% or less than 0.1%. 
Pripravak prema zahtjevima 1 do 15, naznačen time da sadrži 10-20%, poželjno 12-21%, poželjno 15% soli masne kiseline srednjeg lanca poželjno natrijevog oktanoata, 5-10%, poželjno 10% PVP-12, te pri čemu hidrofobni medij sadrži 20-80%, poželjno 30-70% triglicerida poželjno gliceril trikaprilat ili gliceril tributirat ili ricinusovo ulje ili njihovu smjesu, 3-10% surfaktanata, poželjno 6% gliceril monokaprilata i polioksietilen sorbitan monooleata i oko HR P20170929 T1 1% vode i pri čemu je oktreotid prisutan u količini od manje od 33%, ili manje od 25%, ili manje od 10 %, ili manje od 1% ili manje od 0.1%.
The composition or vaccine of any one of claims 1-11 for use in a method of inducing a protective response in an animal comprising at least one administration of the composition or vaccine. 
Pripravak ili cjepivo prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen/o time, da se upotrebljava u postupku cijepljenja životinje, pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
The method for treating asthma according to claim 3, wherein the anti-human TSLP receptor antibody comprises a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 1 i laki lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
A compound having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein: 
HR P20181937 T1 PATENTNI ZAHTJEVI Spoj koji ima sljedeću formulu I:
a container made of moulded pulp with a bottom part (4) for holding a product; and 
- spremnik izrađen od lijevane pulpe s donjim dijelom (4) za držanje proizvoda; i
A marking device according to claim 10, wherein the regulating unit (80) is separated from the striking arm (11) to be unaffected by the pivotal movement of the striking arm (11) when the striking arm (11) is pivoted from the resting position to the striking position. 
Uređaj za označavanje prema zahtjevu 11, naznačen time da da je upravljačka jedinica (80) odvojena od udarne poluge (11) tako da ne bude pod utjecajem zakretnog pokreta udarne poluge (11) kada udarna poluga (11) je zaokrenuta iz položaja mirovanja u udarni položaj.
• isolating said lectin protein from the culture. 
izoliranja navedene bjelančevine tipa lektina iz kulture.
obtain, from a bitstream, a coded block flag representing whether at least one significant transformation coefficient having a non-zero value exists in a transformation block, when the coded block flag represents existence of the at least one significant coefficient in the transformation block, extract information about a horizontal axis direction location and a vertical axis direction location of a last significant transformation coefficient having a non-zero value and included in the transformation block, from a received bitstream wherein the last significant transformation coefficient has last scan index according to a certain scan order among the transformation coefficients, 
kada indikator kodiranog bloka pokazuje postojanje najmanje jednog značajnog koeficijenta u transformacijskom bloku, izvlačenje (1910) informacija o lokaciji smjera vodoravne osi i lokaciji smjera okomite osi zadnjeg značajnog koeficijenta transformacije koji ima vrijednost različitu od nula i nalazi se u transformacijskom bloku, iz primljenog toka bitova naznačen time da zadnji značajni koeficijent transformacije ima zadnji indeks skeniranja prema određenom redoslijedu skeniranja između koeficijenata transformacije;
A method for manufacture of a liquid container for producing and/or storing of liquids, especially alcohol-containing liquids, provided for drinking consumption, wherein an inner wall surface of the liquid container is at least partially, especially substantially entirely, formed as a surface of a solid natural stone and is arranged to come in contact with a liquid to be produced and/or stored in the container, the method comprising the following steps: 
Proces proizvodnje spremnika za tekućinu (10) za proizvodnju i/ili skladištenje pića za konzumiranje, posebice alkoholnih, pri čemu je jedna unutarnja površina stijenke spremnika za tekućinu, bar djelomice, a posebice u potpunosti, sačinjena kao površina od masivnog prirodnog kamena, pri čemu process sadrži sljedeće korake: